CardioComm Solutions, Inc.

CardioComm Solutions, Inc.

EKGGF
CardioComm Solutions, Inc.US flagOther OTC
0.01
USD
- -
- -
2.15MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.02
0.01
0.02
0.01
0.01
0.01
0.01
0.01
- -
0.01
0.01
- -
- -
- -
Basic EPS, GAAP
-0.02
-0.01
-0.01
- -
- -
- -
-0.01
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
-0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.32
-0.04
-0.04
-0.29
-0.03
-0.03
-0.04
-0.04
-0.03
-0.03
-0.03
-0.03
-0.03
-0.03
Tangible Book Value per Share
- -
-0.01
-0.01
- -
- -
- -
-0.01
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
100
107
112
116
135
137
140
141
149
151
151
171
195
194
Sales/Revenue/Turnover
2
2
2
2
2
1
1
1
1
1
1
1
- -
- -
Operating Margin (%)
-101.88
-64.33
-36.24
2.12
9.29
-46.8
-44.44
-9.34
-31.42
-7.41
-23.51
-49.59
-204.71
-204.71
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-1
-1
- -
- -
-1
-1
- -
- -
- -
- -
- -
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-100.45
-63.45
-34.76
-1.48
2.28
-53.65
-121.4
-7.62
0.04
-0.25
-11.11
-36.94
-194.55
-186.97
Working Capital
- -
-1
-1
- -
- -
- -
-1
-1
- -
- -
-1
- -
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
-1
-1
- -
- -
- -
-1
-1
- -
- -
-1
- -
-1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
18.87
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
-0.57
- -
- -
- -
-0.62
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
193
197
198
Market Capitalization
2
1
2

Working Capital

FRC

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-536.24%
17.47%
149.27%
Free Cash Flow
-80.68%
-117.95%
293.89%
Net Income, GAAP
113.37%
613.7%
172.12%
Sales/Revenue/Turnover
-13.2%
-14.51%
-48.33%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Etienne Grima
Full Time Employees
16
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
18 Wynford Drive Toronto ON Canada M3C 3S2
IPO Date
Apr 26, 2010
Business
CardioComm Solutions Inc (EKGGF) develops and markets advanced software hardware products and core laboratory reading services for electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems targeting medical professionals consumers and remote patient monitoring markets worldwide; core offerings include GEMS mobile ECG GEMS mobile RPM HeartCheck CardiBeat mobile ECG device HeartCheck SMART monitoring for consumers; GEMS Sirona GEMS WIN Trident Pro 40L GC3/12 global ECG management systems Body-by-GEMS multiple biosignal monitoring platform supporting blood pressure PO2 temperature ECG heart rate and more; SMART Monitoring rapid ECG reading services; GEMS Rhythm AI for cardiac arrhythmia interpretation; GEMS FLEX and 14-day Holter long-term continuous monitoring (LTCM) platforms. The company founded in 1989 maintains headquarters at 18 Wynford Drive Suite 305 North York Ontario Canada M3C 3S2 and operates primarily in North America with global distribution partnerships targeting hospitals physicians clinical trials telemedicine providers pharmacies and direct-to-consumer channels through FDA-cleared Health Canada-approved ISO 13485/27001-certified HIPAA-compliant technologies. Recent developments encompass Health Canada clearance for GEMS Rhythm AI in September 2024; technology integration with Sony mSafety platform in November 2024 for wearable ECG monitoring post-hospital discharge long-term arrhythmia pharmacy screening and clinical trials; exclusive Quebec distribution rights for TZ Medical ECG devices; Canadian Space Agency contract for GEMS C2M2 connected care prototype; $512000 insider loan facility at 10% interest in November 2025 terminating prior royalty agreement to complete commercialize launch and support GEMS FLEX 14-day Holter/LTCM flagship products; TSX Venture Exchange approval for the loan in November 2025; multiple debt settlements via shares; new CFO appointment in January 2024; CareXM integration for remote ECG monitoring.

Company News

APIChatGPT
  • CardioComm Solutions and Predictiv AI Enter into Strategic AI Collaboration

  • CardioComm Announces Adoption of Quarterly Reporting Exemption Under Coordinated Blanket Order 51-933

  • CardioComm Receives TSX Venture Exchange Approval for Announced Loan Facility

  • CardioComm Terminates Royalty Agreement and Enters into $512,000 Insider Loan Facility to Advance Gems Flex and 14-Day Holter/LTCM Platform

  • CardioComm Solutions Announces Royalty-Based Financing Deal

  • CardioComm Solutions Inc. Announces Insider Purchase of Third-party Loan

  • CardioComm Solutions Closes Shares for Debt Transactions

  • CardioComm Solutions Announces Intention to Settle Outstanding Debt with Issuance of Shares

  • CardioComm Solutions Provides AGM Update Regarding Canada Post Strike

  • CardioComm Solutions Integrates ECG Technology into Sony's mSafety Platform

  • CardioComm Solutions Awarded Canadian Space Agency Contract for Design of Next Generation Connected Care Medical Module Prototype

  • CardioComm Solutions Secures Health Canada Clearance for Artificial Intelligence ECG Interpretation for Multiple Cardiac Arrhythmias

  • CardioComm Solutions, Inc. Secures Exclusive Distribution Rights in Quebec for ECG Medical Devices

  • CardioComm Solutions Enters Loan Agreement

  • Early Warning Press Release Regarding CardioComm Solutions, Inc.

  • CardioComm Solutions Completes Debt Settlement

  • CardioComm Solutions Provides Update Respecting Debt Settlement

  • CardioComm Solutions to Settle Outstanding Debt with Shares

  • CardioComm Solutions Appoints New Board Member and Provides Corporate Update

  • CardioComm Solutions Appoints New CFO